May 17, 2020

GE Healthcare expands its healthcare consulting with purchase of Camden Group

GE Healthcare
Camden Group
Healthcare Global
DaVita Healthcare Partners
2 min
Camden Group will now become the U.S. business unit of GE Healthcare Partners.
In an attempt to expand its healthcare consulting business, General Electric Healthcare recently announced the acquisition of California-based consultin...

In an attempt to expand its healthcare consulting business, General Electric Healthcare recently announced the acquisition of California-based consulting firm Camden Group.

Previously owned by DaVita HealthCare Partners, Camden Group will now become the U.S. business unit of GE Healthcare Partners, as the international conglomerate’s global healthcare advisory firm called GE Healthcare Camden Group.

RELATED TOPIC: Walgreens has purchased Rite Aid; but will it change the healthcare industry?

Last year, the Camden Group ranked as the 20th-largest healthcare management firm according to Modern Healthcare, as it had 350 contracts and $34.2 million in revenue. It’s estimated the new venture will serve over 500 contracts.

The joint venture will deliver strategic and financial consulting, along with services that target population health management, value-based care, clinical integration and care redesign. The partnership is believed to help GE Healthcare Partners work in the U.S. non-acute care space.

RELATED TOPIC: Are high costs causing an unhealthy relationship with patients?

“This blending of capabilities, experience, and resources creates a unique offering for the healthcare industry,” said Laura Jacobs, executive vice president for GE Healthcare Camden Group. “We are excited to join the GE Healthcare family and provide our clients access to the analytics, change management, and activation resources that will support the organizational and clinical changes required to be successful in healthcare now and into the future.”

UK-based GE Healthcare reported US$18.3 billion in revenue last year with US$3 billion in profit, which made up about 12 percent of the healthcare segment revenue for 2014. The other 70 percent of GE’s healthcare segment is comprised of Medical Equipment, which includes clinical systems and diagnostic imaging.

RELATED TOPIC: Why Verisk Analytics is putting its healthcare division up for sale

The healthcare consulting industry has had several major deals this year already, such as Chicago-based Huron Consulting Group’s purchase of Studer Group, as well as healthcare analytics firm Inovalon’s acquisition of Avalere Health in August.

Let's connect!   

Click here to read the latest edition of Healthcare Global magazine!

Share article

Jun 22, 2021

Bachem turns 50 - a timeline

3 min
As Bachem turns 50, we take a look at the company's history

Bachem, a supplier to pharmaceutical and biotechnology companies worldwide, is celebrating its 50th anniversary this month. We take a look at the Swiss company's history.  

1971 - beginnings

Bachem is founded by entrepreneur Peter Grogg in Liestal, a small town near Basel in Switzerland. Grogg started the firm with just two employees, and with a focus on peptide synthesis - peptides are composed of amino acids that have a variety of functions treating health conditions such as cancer and diabetes. 

1977 - 1981 - early growth

Bachem moves its headquarters to the Swiss town of Bubendorf, with eight employees. In 1978 the company produces peptides for use in medicines for the first time. In 1981 production capacity triples and the workforce grows to 150. 

 1987 - 1996 - worldwide expansion

The company expands into the US with Bachem Bioscience, Inc. in Philadelphia. To strengthen its presence in Europe, Bachem opens sales and marketing centres in Germany in 1988. 

Further sales centres open in France in 1993. By 1995 the company employs 190 people. In 1996 it acquires the second largest manufacturer of peptides in the world and forms Bachem California with a site in Torrance. 

 1998 - 2003 - Bachem goes public

Bachem company goes public and lists shares on the Swiss Stock Exchange. Further acquisitions include Peninsula Laboratories, Inc, based in California, and  Sochinaz SA, a Swiss-based manufacturer of active pharmaceutical ingredients.  By 2001, the company has 500 employees and sales reach 141 million CHF.

In 2003 the organisation is given a new legal holding structure to support its continued growth, which remains in place to this day. 

2007 - 2013 - acquisitions

Bachem acquires a brand by Merck Biosciences for ready-to-use clinical trial materials and related services. 

In 2013, together with GlyTech, Inc. Bachem announces the development of a new amino acid that can help to treat multiple sclerosis, with a world market of more than $4 billion. 

In 2015 it acquires the American Peptide Company (APC), which becomes integrated into Bachem Americas. 

2016 - 2019 - a global leader

In 2016 the group opens a new building dedicated to R&D projects and small series production in Bubendorf. With a total of 1,022 employees, the workforce exceeds the 1,000 mark for the first time in the company’s history. Sales are over the 200 million mark for the first time at 236.5 million CHF.
Bachem expands into Asia with the establishment of a new company in Tokyo called Bachem Japan K.K. 

By 2019 Bachem has a growing oligonucleotide portfolio - these are DNA molecules used in genetic testing, research, and forensics. It is hoped this will become a significant product range in the future. 

2020 - COVID-19

Despite the COVID-19 pandemic, Bachem secures its supply of active ingredients, and even increases it in critical areas. Sales exceed the 400 million Swiss franc mark for the first time, and  272 new employees are hired.  

2021 - a milestone anniversary

Bachem celebrates its 50th anniversary and position as a global leader in the manufacture of peptides. While it  remains headquartered in Bubendorf, the company employs 1,500 people at six locations worldwide. In the next five years there are  plans to continue expanding. 

Commemorating the company's anniversary, Kuno Sommer, Chairman of the Board of Directors, said: "Bachem's exceptional success story from a small laboratory to a global market leader is closely linked to Peter Grogg's values, and has been shaped by innovation, consistent quality and cost awareness, as well as by entrepreneurial vision."

Share article